Original article
In der Online-Pressekonferenz anlässlich der 55. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V. (DGTI) warnte Univ.-Prof. Dr. med. Hermann Eichler, Direktor des Instituts für Klinische Hämostaseologie und Transfusionsmedizin, Universität und Universitätsklinikum des Saarlandes, vor einem Blut-Notstand angesichts zu wenig Blutspenden und leerer Blutbanken. Die Frage „Gefährdet die Corona-Pandemie die transfusionsmedizinische Versorgung? beantworte Eichler mit einem eindeutigem Ja.
30.09.2022
In the big summer interview on the occasion of the 10th anniversary as impartial chairman of the Federal Joint Committee, Prof. Josef Hecken spoke about AMNOG developments, the future EU HTA assessment and changes in the benefit assessment process due to the current Statutory Health Insurance Financial Stabilization Act - which can be found in the recently published issue Issue of “Market Access & Health Policy”, the sister magazine of “Monitor Healthcare Research”. In this interview part, Hecken describes his successes, but also what, in his opinion, didn't go so well or went wrong. He also formulates a clear maxim for action in health services research, which would significantly increase the impact of this field of science.
22.09.2022
Medidata, a Dassault Systèmes company, recently announced the publication of the report “European Industry Research Report: The Future of Clinical Trials”. The report is based on new independent research that includes insights from 400 clinical trials executives from Germany, Switzerland, France and the United Kingdom. The aim of the survey was to gain a deeper understanding of how clinical trials have changed in the past two years, how new technologies play a role and what the future could bring in this area.
21.09.2022
Defining the appropriate comparator therapy (CVT) is a central component of the AMNOG benefit assessment and is crucial for assessing the additional benefit of a new drug. Affected pharmaceutical companies can seek advice from the G-BA on the zVT to be determined. However, in numerous cases and at different times, subsequent changes to the zVT occur after consultation. This can sometimes have significant consequences for the evaluation. At the same time, the options for reacting to such changes are very limited. To ensure planning security, the advised ZVT, for which a clinical study was generated, should also be taken into account. At the same time, the transparency of the changes is not sufficient. Early and proactive communication by the G-BA in the event of changes is necessary to ensure the principle of a fair process, reliability and advisory capacity.
21.09.2022
One day before the global patient safety day declared by the World Health Organization (WHO), the new national health goal “patient safety” was presented in Berlin on September 16, 2022 in a dialogue event at the Berlin state representation of Saxony-Anhalt. The publication was developed by the Patient Safety Working Group of the Health Goals Cooperation Group (GVG). With the new national health goal “Patient Safety”, over 140 healthcare organizations from politics, science and society have jointly defined goals and measures to advance patient safety in Germany. The health goal focuses on two goals - patient safety culture and patient safety competence - with further sub-goals assigned to these two main goals.
21.09.2022
presented by: Dr. Alexander Wilke M.Sc., ANIMUS Center for Cognitive Neuroscience, Neuroeconomics and Neuro-Public Health
21.09.2022
Die Katholische Stiftungshochschule München (KSH), eine spezialisierte Hochschule für Sozial-, Pflege-, Gesundheits- und pädagogische Berufe in kirchlicher Trägerschaft, bietet ihren rund 2.500 Studierenden neben Bachelorstudiengängen in der Sozialen Arbeit, Pflege, Gesundheit, Kindheits- und Religionspädagogik konsekutive Masterstudiengänge und Weiterbildungs-Masterstudiengänge an. Einer davon ist der Masterstudiengang „Angewandte Versorgungsforschung“, der die Pflegestudiengänge – von Hebammenkunde über Healthcare-Management bis Pflegepädagogik – ergänzt und von Prof. Dr. Bernd Reuschenbach, Professor für Pflegewissenschaft und Gerontologie am Campus München, geleitet wird.
21.09.2022
presented by Prof. Dr. Dr. Klaus Nagels, Faculty of Law and Economics / Chair of Medical Management and Health Services Research at the University of Bayreuth
21.09.2022
presented by: Markus Greß-Heister MA, LL.M., academic employee in business administration health management at the Baden-Württemberg Lörrach Cooperative State University
21.09.2022
„Ändert man das Ziel, führt das den ganzen Prozess ad absurdum.“ Schon mit diesen wenigen Worten tut Dr. Marco Penske, Volkswirt, Leiter des Bereichs Market Access und Healthcare Affairs bei Boehringer Ingelheim und Stellvertretender Vorsitzender der Deutschen Fachgesellschaft für Market Access, kund, was er von Änderungen der zweckmäßigen Vergleichstherapie nach Beginn von Zulassungsstudien hält (siehe dazu auch das Interview mit Prof. Hecken, G-BA). Ebenso wenig hält er von der im Kabinettsentwurf zum GKV-Finanzstabilisierungsgesetz beinhalteten Gleichschaltung von drei Zusatznutzenkategorien. Wie Hecken befürchtet auch er mehr Opt-outs als bisher, ebenso eine nachhaltige Beschädigung der Versorgung an sich, wenn man seitens der Politik „derartige AMNOG-Leitplanken ändert“.